Healthcare joint venture Haven, started by Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan, has lost its COO Jack Stoddard at just nine months post-hiring, according to a CNBC report.
The former digital health general manager for Comcast told the news channel that he is departing the healthcare play due to personal reasons, including the distance between his home in Philadelphia and Haven’s headquarters in Boston.
Stoddard was the second executive added to the roster of the company last September, just behind CEO Atul Gawende, who was appointed in June.
No replacement has been named since Stoddard officially exited the position last week, according to CNBC.
“Jack played an important role in the early stages of Haven, but we understand his decision to leave the company for family reasons. We want to thank him for all his contributions,” a Haven spokesperson said in a statement, according to the report.
“I wish Atul and the group the best,” Stoddard said, according to CNBC.
Proteor taps Swiggum as U.S. prez, CEO
Advanced prosthetics maker Proteor said last week that it appointed Matthew Swiggum as the new prez and CEO of its U.S. division, effective immediately.
The Tempe, Ariz.-based company said that the addition of Swiggum is part of its plan to continue a global expansion of its prosthetic and orthotic components in the U.S.
“I am excited about the enormous opportunity that lies ahead as part of the PROTEOR USA family, and helping amputees and our customers achieve continued success,” Swiggum said in a prepared statement.
“Having Mr. Swiggum join our team is another significant step in Proteor’s path to build a strong presence in North America. Matthew’s impressive track record in growing a sales organization will be a tremendous asset to further the growth of our franchise. We are all very enthusiastic to begin this new chapter of our journey together,” COO Edouard Archambeaud said in a press release.
Pulmatrix CEO Clarke steps away, Raad steps up
Pulmatrix (NSDQ:PULM) said yesterday that its CEO Dr. Robert Clarke is stepping down, and that it is promoting chief business officer Ted Raad to the corner office.
The Lexington, Mass.-based company said that Clarke will stay on to aid in the transition and will serve as an advisor through to August 14.
Raad joined Pulmatrix in 2017 as CBO and previously held positions with Option Care and Sunovion Pharmaceuticals.
“The Pulmatrix board of directors appreciates the contributions of Dr. Clarke in leading Pulmatrix through the critical stages of an early-stage development-focused company. Bob was integral in the development of Pulmatrix’s iSperse inhaled drug delivery platform and product pipeline. As CEO, Bob also led the company through the transition from a private to public company. We wish the best for Bob. We believe that Ted is well positioned to lead Pulmatrix into a late-stage development and commercial organization. Ted recently led completion of Pulmatrix’s partnership with Cipla Technologies for the development and commercialization of Pulmazole and brings a breadth and depth of executive management, clinical development and commercial experience to the role,” chair Mark Iwicki said in a prepared statement.
“After fifteen years at Pulmatrix growing with the organization from Head of R&D to CSO and ultimately to CEO, I’ve had the opportunity to see every aspect of the company’s business. With the Pulmazole program partnered with Cipla Technologies, and a strong balance sheet for future development, I believe that the business is now heading into a promising phase of its evolution under Ted’s capable leadership. I look forward to the future success of Pulmatrix as the Company’s products get to patients in need,” Dr. Robert Clarke said in a press release.
“I personally want to thank Bob for his contributions and bringing me to the company. Pulmatrix has the potential to transform patient care in respiratory disease. In addition to Pulmazole beginning Phase 2, we look forward to advancing PUR1800 towards the clinic. We have a robust pipeline where each product has the potential to positively impact patient lives,” prez & CEO Ted Raad said in prepared remarks.
Boston Scientific names Monson as chief accounting officer
Boston Scientific (NYSE:BSX) said last week that it lifted current finance VP Jonathan Monson to the position of chief accounting officer and global controller.
Monson previously served as the Marlborough, Mass.-based company’s finance VP and controller for its urology and pelvic health biz, beginning in 2016. Prior to that, Monson acted as corporate accounting VP from 2008 to 2016.
Fresenius finds new roles for freshly onboarded NxStage execs
Fresenius Medical Care (NYSE:FMS; ETR:FRE) last week announced a number of changes to its leadership roster related to its merger with NxStage Medical, including moving former NxStage CEO and Founder Jeff Burbank to a CTO position.
The Waltham, Mass.-based company said that former NxStage prez Joe Turk will serve as home and critical care therapies prez, a newly formed team within the company.
“I’m thrilled that we are bringing these talented groups together under Jeff and Joe’s leadership to ensure we continue to seamlessly integrate the incredible experience and groundbreaking technology from the NxStage team directly into Fresenius Medical Care North America. Under their leadership, we will centralize our focus on home therapies that are giving life back to our patients with kidney failure by offering more freedom, control and better health,” Fresenius CEO Bill Valle said in a prepared statement.
